Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
INDIA's Congress party leader Rahul Gandhi has sharply criticised prime minister Narendra Modi's handling of the conflict with China, claiming that 4,000sqkm of Indian territory in Ladakh have been "occupied" by Chinese troops.
Speaking at a press conference at the National Press Club in Washington, Gandhi labelled the situation a "disaster" and argued that no leader should be seen as having managed such a situation well.
Gandhi compared the issue to how the US would respond if its territory were similarly occupied, questioning whether any American president could claim to have handled it well under such circumstances.
"I don't think Modi has handled China well. There’s no reason for Chinese troops to be sitting in our territory," he said.
Despite his strong criticism on China, Gandhi indicated that his Congress party is in broad agreement with the Modi-led government on other major foreign policy issues.
Rahul Gandhi holds meeting with US lawmakers in Washington DC. (ANI Photo)
He expressed support for the government's stance of not engaging in talks with Pakistan unless terrorism from its side ceases. He also agreed with the government's concerns over extremist elements in Bangladesh, stating that it is crucial for the Bangladeshi government to address such issues promptly.
Regarding India-US relations, Gandhi noted continuity in the approach across political parties, recognising the relationship as key for both nations.
"I don’t see a significant diversion from our approach to the US. The relationship has bipartisan support in both countries," he said.
On internal affairs, Gandhi was clear that he does not want any role for the US in India’s domestic matters. "The fight for democracy in India is an Indian fight," he said. "Indian democracy is more than just any normal democracy because of its size. It is an asset not just for India, but for the rest of the world."
The leader of opposition in Indian parliament did not shy away from raising concerns about the state of democracy in India over the past decade, alleging that it has been "broken" but is now "fighting back."
He cited instances like the Maharashtra government being "taken away" from his party, Congress, through questionable means and discussed the challenges his party faced, including financial constraints during elections.
"We fought an election with our bank accounts frozen... Now, you can have a resilient voter. You still need to run campaigns," he noted. He also pointed to the legal challenges he faces, including being the only person in Indian history to receive a prison sentence for defamation, and criticised Modi’s approach to governance and his claims of having a "direct link to God."
Gandhi also touched upon the Israel-Palestine conflict, condemning both the Hamas attack on Israel on October 7 last year and Israel's subsequent actions that he said resulted in the killing of innocent civilians. "I'm against violence of any kind," he said, warning that the scale of violence could be detrimental to Israel itself.
His remarks came during an unofficial four-day trip to the US, where he met with lawmakers and discussed various geopolitical concerns.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.